Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-02
2010-10-05
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07807688
ABSTRACT:
Tri-heterocyclic compound of formula (I)wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR2, NR13, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; R1is alkyl, alkenyl, alkynyl, NR4R5, OR6etc.; R3is carbocyclic ring, heterocyclic ring;and a pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical comprising them as an active ingredient.A compound of formula (I) is useful, in order to possess corticotropin releasing factor receptor antagonistic activity, for the prevention and/or treatment of depression, anxiety, eating disorder, posttraumatic stress disorder, peptic ulcer, irritable bowl syndrome, Alzheimer's disease, drug addiction or alcohol dependence syndrome etc.
REFERENCES:
patent: 5420128 (1995-05-01), Kiyokawa et al.
patent: 5843951 (1998-12-01), Inoue et al.
patent: 7034153 (2006-04-01), Nakai et al.
patent: 92/06096 (1992-04-01), None
patent: 97/11946 (1997-04-01), None
patent: 99/64422 (1999-12-01), None
patent: 00/27846 (2000-05-01), None
patent: 00/27850 (2000-05-01), None
Science, 226, 1342-1343 (1984).
Science, 273, 1561-1564 (1996).
Endocrinology, 137, 5747-5750 (1996).
Am. J. Physiol., 253, G582-G586 (1987).
Psychopharmacology, 137, 184-190 (1998).
Soc. Neurosci. Abstr., 807.5 (2000).
Palmer, Pharmacotherapy for Alzheimer's Disease: Progress and Prospects, TRENDS in Pharmacological Sciences, vol. 23, No. 9 (2002).
Sivakamasundari et al., “Pyrroloquinolines: Part IV- Synthesis of 1-Aryl-1H-pyrrolo[2,3-b]quinolines”, Indian J. of Chem., 1987, 26B:744-747.
Tominaga et al., “Synthesis of Methylthiomaleimides for the Preparation of Pyridazines and Related Compounds”, Journal of Heterocyclic Chemistry, 2002, 39(3):571-591.
Colin A. Leach et al., “Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo [3,2-c] quinolines: Effect of the 4-Substituent”, J. Med. Chem., 1992, 35(10):1845-1852.
Leon Smith et al., “A novel and highly efficient synthesis of the aza analogs of tacrine”, Tetahedron Letters, 1999, 40(31):5643-5646.
Gerhard Himbert et al., “(Aminoethinyl)metallierungen, 14 Cyclisierung von N1, N2-Diaryl-N1-Phenacyl-3-aminopropiolamidinen”, Liebigs Ann. Chem., 1985, 7:1389-1397.
Alan M. Palmer, “Pharmacotherapy for Alzheimer's disease: progress and prospects”, TRENDS in Pharmacological Sciences, 2002, 23(9), 426-433.
Jones et al., “British Society of Gastroenterology guidelines for the management of irritable bowel syndrome”, GUT 2000, 47, 1-19.
Bastin et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, Organic Process Research and Development, 2000, 4, 427-435.
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 1977, 66(1), 1-19.
Kagamiishi Yoshifumi
Nakai Hisao
Leeser Erich A
Ono Pharmaceutical Co. Ltd.
Sughrue & Mion, PLLC
Wilson James O
LandOfFree
Tri-heterocyclic compounds and a pharmaceutical comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tri-heterocyclic compounds and a pharmaceutical comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tri-heterocyclic compounds and a pharmaceutical comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162580